|
Limited Versus Extended Lymph Node Dissection During Radical Prostatectomy in Patients With Localized or Locally Advanced Prostate Cancer
RECRUITINGN/ASponsored by N.N. Alexandrov National Cancer Centre
Actively Recruiting
PhaseN/A
SponsorN.N. Alexandrov National Cancer Centre
Started2025-10-29
Est. completion2030-05-30
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07308990
Summary
This is a randomized controlled study assessing outcome of low (no or limited) versus high (limited or extended) extent of lymph node dissection in addition to radical prostatectomy in patients with operable localized or locally advanced prostate cancer.
Eligibility
Age: 18 Years+Sex: MALEHealthy volunteers accepted
Inclusion Criteria: 1. Age over 18 years. 2. Histologically confirmed localized or locally advanced prostate cancer (adenocarcinoma without a neuroendocrine component). 3. No evidence of metastatic spread of the tumor 4. Local resectability of the tumor according to digital rectal examination and/or CT and/or MRI of the pelvis 5. Patients are suitable for radical prostatectomy based on their comorbidities and life expectancy. 6. Signed informed consent to participate in the study. Exclusion Criteria: 1. Presence of another active malignant invasive neoplasm. 2. Contraindication to pelvic lymph node dissection (e.g., history of radiation therapy to the pelvis). 3. The evidence of metastases in regional lymph nodes according to preoperative examination data (including PET/CT with PSMA). 4. Severe concomitant disease limiting participation in the study.
Conditions2
CancerProstate Cancer Patients Undergoing Radical Prostatectomy
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorN.N. Alexandrov National Cancer Centre
Started2025-10-29
Est. completion2030-05-30
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07308990